Immunome (IMNM) CSO Jack Higgins Sells 13,200 Shares, Exercises Options

What Happened
Jack Higgins, Chief Scientific Officer of Immunome (IMNM), reported multiple transactions on 2026-09-11. He exercised/converted derivatives to acquire a total of 36,000 shares (18,000 shares exercised at $1.35, cost $24,300; 18,000 shares converted at $0.00). The same day he sold 13,200 shares in an open-market sale at $25.32 each for proceeds of $334,224 and gifted 8,800 shares (no proceeds).

Key Details

• Transaction date: September 11, 2026; Form 4 filed September 15, 2026 (timely — weekend fell between trade and filing).
• Exercise/conversion (M): 36,000 shares acquired total — 18,000 at $1.35 (paid $24,300); 18,000 at $0.00 (conversion).
• Sale (S): 13,200 shares sold at $25.32, total proceeds $334,224.
• Gift (G): 8,800 shares transferred as a gift; disposed value $0.
• Shares owned after transaction: not specified in the portions provided.
• Footnotes of note:
  • F1: The sales were made under a pre-established Rule 10b5-1 trading plan adopted Dec 19, 2025.
  • F2: The gifted shares were deposited into a custodial account for his child under the Uniform Transfer to Minors Act; Higgins disclaims beneficial ownership of those shares.
  • F3: Option vesting schedule: 25% vested May 1, 2023, then 1/36th of remaining shares monthly thereafter (continuous service required).

Context

• The filing shows both option exercises/conversions and an open-market sale on the same day; the Form 4 does not specify whether the sold shares were the newly acquired shares or pre-existing holdings.
• Gifts reflect transfers for estate or family planning and are not a direct signal of market sentiment.
• The sale was executed under a 10b5-1 plan, which typically makes same-day sales part of a pre-set schedule rather than ad-hoc trades.